JOP20250053A1 - البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميد - Google Patents
البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميدInfo
- Publication number
- JOP20250053A1 JOP20250053A1 JOJO/P/2025/0053A JOP20250053A JOP20250053A1 JO P20250053 A1 JOP20250053 A1 JO P20250053A1 JO P20250053 A JOP20250053 A JO P20250053A JO P20250053 A1 JOP20250053 A1 JO P20250053A1
- Authority
- JO
- Jordan
- Prior art keywords
- piperidine
- methyl
- gallic acid
- nicotinamide
- pyrazolpyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263404232P | 2022-09-07 | 2022-09-07 | |
| PCT/US2023/073508 WO2024054814A1 (en) | 2022-09-07 | 2023-09-06 | Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20250053A1 true JOP20250053A1 (ar) | 2025-03-06 |
Family
ID=88204177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2025/0053A JOP20250053A1 (ar) | 2022-09-07 | 2025-03-06 | البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميد |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240116932A1 (https=) |
| EP (1) | EP4584270A1 (https=) |
| JP (2) | JP7541606B2 (https=) |
| KR (1) | KR20250057022A (https=) |
| CN (1) | CN120187720A (https=) |
| AR (1) | AR130417A1 (https=) |
| AU (1) | AU2023338199A1 (https=) |
| CA (1) | CA3266872A1 (https=) |
| CL (1) | CL2025000596A1 (https=) |
| CO (1) | CO2025002467A2 (https=) |
| CR (1) | CR20250077A (https=) |
| DO (1) | DOP2025000054A (https=) |
| IL (1) | IL319342A (https=) |
| JO (1) | JOP20250053A1 (https=) |
| MX (1) | MX2025002687A (https=) |
| PE (1) | PE20251400A1 (https=) |
| TW (1) | TWI862146B (https=) |
| WO (1) | WO2024054814A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025259519A1 (en) | 2024-06-13 | 2025-12-18 | Eli Lilly And Company | Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3) |
| WO2026037249A1 (zh) * | 2024-08-13 | 2026-02-19 | 海思科医药集团股份有限公司 | 取代杂环类衍生物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1962600B1 (en) * | 2005-12-08 | 2013-05-01 | New Form Pharmaceuticals Inc. | Metronidazole cocrystals |
| PH12012000132A1 (en) * | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
| CN102964384B (zh) * | 2012-11-09 | 2015-06-24 | 中山大学 | 阿德福韦酯没食子酸共晶及其制备方法和组合物 |
| EP3752159A4 (en) * | 2018-02-13 | 2021-11-24 | Transgenex Nanobiotech, Inc. | NEW CRYSTALLINE FORMS OF TAMIBAROTENE FOR CANCER TREATMENT |
| WO2020131627A1 (en) * | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN111574359A (zh) * | 2019-02-19 | 2020-08-25 | 愈磐生物科技（苏州）有限公司 | 乐伐替尼-没食子酸共晶晶型及其应用 |
| CN113943284B (zh) * | 2020-07-15 | 2023-12-19 | 中国医学科学院药物研究所 | 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途 |
| AR125588A1 (es) * | 2021-03-04 | 2023-08-02 | Lilly Co Eli | Compuestos inhibidores de fgfr3 |
-
2023
- 2023-09-06 EP EP23777475.7A patent/EP4584270A1/en active Pending
- 2023-09-06 CA CA3266872A patent/CA3266872A1/en active Pending
- 2023-09-06 KR KR1020257010708A patent/KR20250057022A/ko not_active Ceased
- 2023-09-06 IL IL319342A patent/IL319342A/en unknown
- 2023-09-06 CN CN202380077374.0A patent/CN120187720A/zh active Pending
- 2023-09-06 PE PE2025000482A patent/PE20251400A1/es unknown
- 2023-09-06 WO PCT/US2023/073508 patent/WO2024054814A1/en not_active Ceased
- 2023-09-06 AU AU2023338199A patent/AU2023338199A1/en active Pending
- 2023-09-06 CR CR20250077A patent/CR20250077A/es unknown
- 2023-09-06 US US18/462,286 patent/US20240116932A1/en active Pending
- 2023-09-07 TW TW112133993A patent/TWI862146B/zh active
- 2023-09-07 AR ARP230102376A patent/AR130417A1/es unknown
- 2023-09-07 JP JP2023145013A patent/JP7541606B2/ja active Active
-
2024
- 2024-08-16 JP JP2024136962A patent/JP2024153948A/ja active Pending
-
2025
- 2025-02-28 CO CONC2025/0002467A patent/CO2025002467A2/es unknown
- 2025-03-04 CL CL2025000596A patent/CL2025000596A1/es unknown
- 2025-03-06 DO DO2025000054A patent/DOP2025000054A/es unknown
- 2025-03-06 JO JOJO/P/2025/0053A patent/JOP20250053A1/ar unknown
- 2025-03-06 MX MX2025002687A patent/MX2025002687A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024054814A1 (en) | 2024-03-14 |
| JP2024037713A (ja) | 2024-03-19 |
| CO2025002467A2 (es) | 2025-03-17 |
| CN120187720A (zh) | 2025-06-20 |
| CR20250077A (es) | 2025-04-02 |
| CA3266872A1 (en) | 2024-03-14 |
| EP4584270A1 (en) | 2025-07-16 |
| JP7541606B2 (ja) | 2024-08-28 |
| US20240116932A1 (en) | 2024-04-11 |
| AU2023338199A1 (en) | 2025-03-20 |
| DOP2025000054A (es) | 2025-03-31 |
| CL2025000596A1 (es) | 2025-04-25 |
| PE20251400A1 (es) | 2025-05-22 |
| JP2024153948A (ja) | 2024-10-29 |
| KR20250057022A (ko) | 2025-04-28 |
| IL319342A (en) | 2025-05-01 |
| AR130417A1 (es) | 2024-12-04 |
| TWI862146B (zh) | 2024-11-11 |
| MX2025002687A (es) | 2025-04-02 |
| TW202428260A (zh) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20250053A1 (ar) | البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميد | |
| CO2022006858A2 (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
| Nguyen et al. | Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: A survey of recent patent literature | |
| Rewcastle et al. | Tyrosine kinase inhibitors. 14. Structure− activity relationships for methyl-amino-substituted derivatives of 4-[(3-bromophenyl) amino]-6-(methylamino)-pyrido [3, 4-d] pyrimidine (pd 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the egf family of growth factors | |
| Hamby et al. | Structure− activity relationships for a novel series of pyrido [2, 3-d] pyrimidine tyrosine kinase inhibitors | |
| Wu et al. | Synthesis and screening of 3-MA derivatives for autophagy inhibitors | |
| EP1079826B1 (en) | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases | |
| GEAP202215630A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| JP2005531488A (ja) | 甲状腺癌を処置するためのｅｇｆ受容体阻害剤 | |
| Lv et al. | Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment | |
| NO20072747L (no) | Fremgangsmate for fremstilling av indazolforbindelser | |
| UY27370A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células y métodos para su utilización | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| ECSP056246A (es) | DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA | |
| MX2023005626A (es) | Derivados de pirazolo[1.5-a]pirazina como inhibidores de la btk. | |
| MY210039A (en) | Compounds, compositions, and methods for modulating cdk9 activity | |
| MX2021002051A (es) | Imidazo[1,2-b]piridaziinas como inhibidores de trk. | |
| JOP20240257A1 (ar) | مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها | |
| ECSP066767A (es) | Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa | |
| MX2021000683A (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de trk. | |
| Bischoff et al. | Novel pharmacological modulators of autophagy and therapeutic prospects | |
| PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| Ma et al. | Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors | |
| CL2025000087A1 (es) | Compuestos inhibidores de tirosina quinasa 2 y uso. | |
| US20240366536A1 (en) | Modulators of a potassium channel and of trpv1 channel and uses thereof |